More rapid.
More automated.

More complete myeloid genomic profiling
with NGS.


Myeloid Testing should
be fast

Myeloid malignancy samples can be challenging to analyze. They are complex, heterogeneous, and have the potential to proliferate rapidly. To get meaningful genetic insights, you need a rapid and streamlined approach for studying all key mutations.



On-Demand Webinars



Genomic profiling from initial assessment to detection of measurable residual disease (MRD): how NGS can rapidly deliver key insights for myeloid neoplasms.

Dr. Bevan Tandon of Pathline Labs will review ongoing research in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days. He will also share his experience with the upcoming Oncomine Myeloid MRD Assay (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assessment that can identify mutations occurring at very low frequencies. Dr. Tandon will share recent analytical data from his team and offer his perspective on the value of NGS in hematopathology studies.




Bevan Tandon, MD
Director, Hematopathology and Molecular Pathology, Pathline



Rapid Next-Generation Sequencing for the Study of Acute Myeloid Leukemia


Dr. Diana Morlote

University of Alabama at Birmingham


During this presentation, Dr. Diana Morlote, assistant professor of pathology at the University of Alabama at Birmingham, discusses the recent implementation of a rapid, automated next-generation sequencing (NGS) assay in her research laboratory for genomic profiling of Acute Myeloid Leukemia (AML) and other related hematological disorders. The data being presented was collected from several archive cases using the Oncomine Myeloid Assay GX and the Genexus System. Analytical performance is discussed for various key mutations detected using DNA inputs. Dr. Morlote describes how this solution addresses key challenges with molecular analysis of AML and other related malignancies. This research furthers our understanding of malignant hematological disorders and may lead to better care in the future.






Oncomine Myeloid Assay GX V2

The Ion Torrent ™ Oncomine™ Myeloid Assay GX V2 on the Ion Torrent™ Genexus™ System provides a complete next-generation sequencing (NGS) solution that can deliver a comprehensive myeloid mutational report in as little as one day.

Rapid Automated Comprehensive Trusted Insightful
New call-to-action New call-to-action New call-to-action New call-to-action New call-to-action
Go from specimen to report in as little as one day.

Process samples with just 20 minutes of hands-on time required.

Simultaneously profile 45 key genes (DNA) and 35 fusion drivers (RNA), covering >700 unique fusions.

Reliably detect a wide range of variants, including challenging-to-sequence targets like FLT3-ITD.

Get an annotated variant report, including links to latest relevant evidence.


Profile All Key Myeloid Mutations with one test

Simultaneously interrogate 45 DNA target genes and 35 fusion driver genes (RNA). This broad fusion panel allows you to sequence over 700 unique fusion transcripts. Gene content on the panel has been curated to cover relevant targets for all the major myeloid disorders—AML, MDS, MPN, CML, CMML, and JMML.



Hot Spot Genes


Full Genes


Fusion Drivers


Expression Genes


Expression Controls

Complete Coverage of Key Genes

Newly added genes shown in green below.

Detect multiple types of mutations
at once

Myeloid samples frequently harbor mutations in difficult-to-sequence regions of the genome.

The Oncomine Myeloid Assay GX v2 has been carefully engineered to reliably detect all relevant mutations associated with myeloid malignancies, including targets in challenging genes like CEBPA, FLT3, CALR and more.


  • Single nucleotide variants
  • Insertions and Deletions
  • Tandem duplications
  • Gene fusions

Scientific Posters

Poster: 2022 American Association of Cancer Research (AACR) Meeting

Fully automated sample-to-report NGS workflow for comprehensive genomic profiling of myeloid neoplasm research samples

Sarah Brozio, et al. - Thermo Fisher Scientific

View Poster





Recent Performance Data

AMP 2021 Poster: Development of an automated genomic profiling assay for myeloid malignancies research

View our e-Poster published in the AMP 2021 Digital Experience Program to see recent data using the Oncomine Myeloid Assay GX v2.

View Poster






It's NGS made easy

A highly integrated workflow lets you go from specimen to report with about 20 minutes of hands-on time required*. It’s never been easier to implement myeloid NGS testing in your lab.



Automate your workflow from specimen to report

Start with any common myeloid specimen type, including whole blood, bone marrow, or peripheral blood leukocytes. From there, the Genexus System integrates and automates nucleic acid extraction, purification, quantification, library preparation, sequencing, analysis and reporting within a single software ecosystem. 


All Common Species

Whole Blood

Peripheral Blood Leukocytes (PBLs)

Bone Marrow


Automated Workflow

Nucleic acid extraction and quantification

Library preparation


Reporting & analysis


Annotated Variant Report

Biomarkers linked to relevant evidence from public data sources

Clear And Concise Reports

Ion Torrent Oncomine Reporter is a curated knowledgebase and reporting software that links biomarkers to relevant evidence and enables custom reporting. These tools help simplify the bioinformatics workflow and enable you to focus on finding the biological meaning of your data.

See Sample Report







Additional Resources

Book a demo or request a quote

Are you ready to speak to a representative?



For Research Use Only. Not for use in diagnostic procedures.